A New Co-Suspension MDI Platform: Scientific Foundations of Mono, Dual and Triple Combination Products
Lechuga-Ballesteros D, Vehring R, Dwivedi SK.
RDD Europe 2011. Volume 1, 2011: 101-112.
Abstract:
Product development and clinical use of inhaled medicines may be confounded by drug delivery differences between various doses and dosage forms, or by transition from a monotherapy to combination therapy. Pressurized metered dose inhalers (pMDIs) are the most widely prescribed inhalation dosage form, yet formulation tunability across doses, versatility with drugs possessing different physicochemical attributes, and universal applicability to monotherapy or combination products types, have been difficult targets to achieve with conventional pMDI formulation approaches. This article describes a novel platform which involves the use of drug-free spray dried phospholipid microparticles to generate tunable, uniform and stable pMDI co-suspensions with micronized drug crystals, across wide dose ranges, for the major classes of respiratory therapeutics in mono, dual and triple therapy product formats.
I have a subscription
Log in for instant access.
I do not have a subscription
Purchase Article (in PDF format)
